レイ症候群とアスピリン. ドーゼ・レスポンス効果の証拠
P F Pinsky1, E S Hurwitz, L B Schonberger
1Division of Viral Diseases, Centers for Disease Control, Atlanta, GA 30333.
JAMA
|August 5, 1988
まとめ
この研究では,病気中のアスピリンの高用量がレイ症候群のリスク,特に中間レベルを増加させることが判明しました. 投与量の違いは,病気の3日目と4日目に最も顕著でした.
科学分野:
- 小児科は小児科です.
- エピデミオロジー エピデミオロジー
- 薬理学 薬理学とは
背景:
- レイ症候群 (Reye's syndrome) は,子供や青少年に影響を与える珍しいが深刻な疾患である.
- アスピリンの使用はレイ症候群と関連しているが,投与量反応関係についてはさらなる調査が必要である.
研究 の 目的:
- アスピリンの投与量とレイ症候群の発達との関係を分析する.
- 特定のアスピリン用量のレベルがより大きなリスクをもたらすかどうかを判断する.
主な方法:
- レイ症候群と薬剤に関する公衆衛生サービスの主要な研究からのデータの分析.
- レイ症候群の症例患者と,以前の病気の時の対照群で受けたアスピリンの投与量を比較した.
主要な成果:
- 症例患者は,対照群よりも,平均日用量および最大日用量アスピリンの投与量を大幅に高めた.
- 過剰なリスクは,主にアスピリンの中間用量 (15~27 mg/kg/日) と関連していました.
- 症例患者と対照群の最大の用量差は,病気の3日目と4日に発生しました.
結論:
- アスピリンの投与量は,レイ症候群の発症の重要な要因である.
- 中途半端なアスピリンの用量は,著しいリスクを伴います.
- 最適な小児熱管理に関するさらなる研究が必要である.
関連する概念動画
Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Dose-Response Relationship: Overview
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

